pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 10·1 min read
save

German parliament approves cost-cutting health bill, pharma industry warns of exit risk

Jul 10, 2026·read at Endpoints ↗RegulatoryNegative

German federal parliament voted to pass a bill aimed at reducing domestic healthcare expenditures.

The legislation seeks to curb spending on medicines and other health services as part of a broader effort to control the nation's budget.

The country's main pharmaceutical trade association criticized the measure, saying it could force drugmakers to leave the market.

The debate highlighted tension between cost-containment goals and industry concerns about profitability and patient access.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “German lawmakers pass cost-saving bill that drugmakers say will drive them out”

read at Endpoints ↗
83 words · retrieved Jul 10
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints
  • 2h agoSuperluminal secures $60M for Phase 1 of genetic obesity drugEndpoints
  • 2h agoGSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontEndpoints
  • 10h agoUltragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsEndpoints
  • 17h agoFDA leaders project enhanced scrutiny of foreign dataEndpoints